Fluvoxamine

Early treatment with oral fluvoxamine plus inhaled budesonide reduced the incidence of progression to severe disease among high-risk outpatients with COVID-19, according to research published in Annals of Internal Medicine.

The FDA declined a request to authorize an inexpensive generic antidepressant and obsessive-compulsive disorder medication for emergency use as an outpatient treatment for COVID-19.

In this episode, Joel M. Gelfand, MD, MSCE, and Leonard H. Calabrese, DO, are joined by Paul E. Sax, MD, as they discuss advances in the outpatient management of COVID-19 and emerging information about the omicron variant.

The antidepressant fluvoxamine reduced the need for hospitalization among high-risk patients with COVID-19, according to results of the randomized, placebo-controlled TOGETHER trial.